Generics makers prepare for challenges ahead of patent cliff's end

Opportunities are drying up for makers of generic drugs as the value of treatments set to lose their patents and be sold as generics is anticipated to drop by more than half next year to around $17 billion, a Crédit Agricole Securities analysis found. Many makers of generics are trying to redefine themselves through acquisitions, branded products or treatments that are hard to produce.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief: